A Study of Local Ablative Therapy (LAT) in People With Non-Small Cell Lung Cancer (NSCLC)

Sponsor: Memorial Sloan Kettering Cancer Center

Sponsor score: 60
Inactive

ClinicalTrials ID:NCT05429320

Patient View

This study evaluates the impact of local ablative therapy (LAT) on reducing minimal residual disease (MRD) in metastatic NSCLC. Eligible participants must not have complete radiographic response or CNS-only disease. Exclusions include recent malignancies and serious co-morbidities. Interventions include LAT and ctDNA blood collection to monitor MRD levels.

Patient Parameters

Program Overview

The purpose of this study is to see whether receiving local ablative therapy (LAT) when minimal residual disease/MRD levels are rising can reduce MRD levels and control metastatic non-small cell lung cancer/NSCLC longer compared to systemic therapy.

Eligibility Criteria

Exclusion Criteria

  • At the time of therapeutic phase enrollment, complete response radiographically (no lesions to target)
  • Patients with CNS-only disease (due to limited capacity of peripheral blood ctDNA to detect CNS lesions)
  • Planned treatment by targeted agents (e.g. tyrosine kinase inhibitors) or patient not a candidate for systemic therapy
  • Serious medical co-morbidities precluding radiotherapy or ablation, determined at the discretion of the treating investigator.
  • At the time of therapeutic phase enrollment, pregnant or lactating women.
  • Physical limitation to undergo stereotactic radiotherapy.
  • Other active malignancy within the last year except for basal cell carcinoma of the skin and in situ malignancy even if without evidence of disease.

Get This Program In Your Inbox

You can sign up and apply your patients for this program.